Denali Therapeutics Inc. DNLI Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s operating cash flow?
- Denali Therapeutics Inc. (DNLI) reported operating cash flow of -$131.2M in Q1 2026.
- How has Denali Therapeutics Inc.'s operating cash flow changed year-over-year?
- Denali Therapeutics Inc.'s operating cash flow increased by 0.2% year-over-year, from -$131.47M to -$131.2M.
- What is the long-term trend for Denali Therapeutics Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s operating cash flow has grown at a 18.2% compound annual growth rate (CAGR), from -$211.39M to -$412.6M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.